GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metacrine Inc (OTCPK:MTCR) » Definitions » Earnings Yield %

Metacrine (Metacrine) Earnings Yield % : N/A% (As of May. 07, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Metacrine Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-05-07), the stock price of Metacrine is $0.0014. Metacrine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.91. Therefore, Metacrine's earnings yield of today is N/A%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Metacrine's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Metacrine Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Metacrine's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=-0.911/0.0014
=N/A %

Metacrine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.911 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


Metacrine  (OTCPK:MTCR) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Metacrine Earnings Yield % Related Terms

Thank you for viewing the detailed overview of Metacrine's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Metacrine (Metacrine) Business Description

Traded in Other Exchanges
N/A
Address
3985 Sorrento Valley Boulevard, Suite C, San Diego, CA, USA, 92121
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.
Executives
Michael York officer: Chief Business Officer C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Preston Klassen director, officer: President & CEO 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Hubert C Chen officer: Chief Medical Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Julia C. Owens director C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451